| Title |
Multiparametric MRI fusion-guided prostate biopsy for detection of clinically significant prostate cancer eliminates the systemic prostate biopsy / |
| Authors |
Matulevičius, Augustinas ; Bakavičius, Arnas ; Ulys, Albertas ; Trakymas, Mantas ; Ušinskienė, Jurgita ; Naruševičiūtė, Ieva ; Sabaliauskaitė, Rasa ; Žukauskaitė, Kristina ; Jarmalaitė, Sonata ; Jankevičius, Feliksas |
| DOI |
10.3390/app121910151 |
| Full Text |
|
| Is Part of |
Applied sciences-Basel.. Basel : MDPI. 2022, vol. 12, iss. 19, art. no. 10151, p. 18-28.. eISSN 2076-3417 |
| Keywords [eng] |
prostate cancer ; mpMRI ; US ; TRUS-guided biopsy |
| Abstract [eng] |
The primary objective of this study was to demonstrate the high accuracy of multiparametric magnetic resonance imaging and ultrasound fusion (mpMRI/US)-guided targeted prostate biopsy for the detection of clinically significant prostate cancer (PCa) and to show that adapted systematic biopsy (AdSB) does not provide additional benefit in detecting clinically significant prostate cancer (PCa). In total, 283 patients have been included in the study. All patients underwent the mpMRI/US biopsies, which have been performed with the “BioJet” fusion system (D&K Technologies, Barum, Germany) using the transperineal approach by a single interventional radiologist. Lesion-targeted and systematic biopsies have been done when 2–4 cores have been taken from each PI-RADS 3–5 lesion, followed by AdSB. This study demonstrated that targeted prostate biopsy is sufficient for safe and sensitive identification of clinically significant PCa in primary biopsy-naïve cases without the need to perform adapted systematic biopsy. |
| Published |
Basel : MDPI |
| Type |
Journal article |
| Language |
English |
| Publication date |
2022 |
| CC license |
|
